Genticel to meet institutional investors during the Large and Midcap Event in Paris, October 2 and 3, 2014 (AcT)

GENTICEL (Euronext Paris and Brussels: FR0011790542 - GTCL), a French biotechnology company and leading developer of therapeutic vaccines, today announces its participation in the 14^th edition of Large & Midcap Event taking place in Paris on October 2 & 3, 2014.

During this event, institutional investors and Euronext-listed companies will hold one-to-one meetings. Benedikt Timmerman, founder and CEO of Genticel, will expound on the latest developments of Genticel's therapeutic vaccines programs aimed at preventing cervical cancer in women who already carry human papilloma virus (HPV).

For more information on this event, including registration, visit: www.midcapevents.com/midcap2014/home/

Upcoming financial announcements (after Euronext stock exchange closing):

Genticel will participate in several meetings with investors during the coming months:

About Genticel

Genticel is a French biopharmaceutical company specialized in the development of therapeutic vaccines aimed at eliminating, at an early stage, the human papillomavirus (HPV) responsible for cervical cancer.

Genticel is developing ProCervix, a first therapeutic vaccine in Phase II clinical trials, designed to eliminate cervical cells infected with HPV 16 and/or HPV 18. The Company has also established Vaxiclase, a technology platform ideally adapted for use in early-intervention immunotherapies against multiple infectious or cancerous diseases. This platform is being used to develop a second therapeutic vaccine candidate, now in its preclinical stage, targeting six of the most pertinent HPV strains in terms of global epidemiology.

Genticel is based in Paris and Toulouse and was awarded the 2013 Innovation Prize by the ‘Grands Prix de l'Economie'.

Since April 4, 2014, Genticel shares have been listed on the regulated Euronext markets in Paris and Brussels.

For more information, please visit Genticel's website www.genticel.com